After weeks of legal drama, Ozempic is coming Hims & Hers, a telehealth company.

Novo Nordisk came to an agreement with the company to offer various doses of the GLP-1 medication for DTC customers.¹ This comes after Hims & Hers was barred from selling compounded GLP-1 medications earlier this year.

How did Novo Nordisk and Hims & Hers reach this agreement?

In a press release, Novo Nordisk president and CEO Mike Doustdar said, “This agreement with Hims & Hers is a meaningful win for patients in the United States. By expanding access through leading telehealth providers and digital care platforms, we are helping to connect more people with our FDA-approved medicines, which have been evaluated for safety and efficacy. Wegovy® is not simply an obesity therapy. It is a clinically proven treatment that helps adults with obesity lose weight while also reducing the risk of cardiovascular events in patients who also have heart disease. That combination of powerful weight loss efficacy and proven risk reduction is what makes Wegovy® truly distinct. We all want better health. Our goal is simple: ensure that every patient who can benefit from our medicines has the opportunity to access them, wherever they choose to receive care.”

Hims & Hers will offer the following Novo Nordisk GLP-1 medications:

• 0.5 mg Ozempic injection
• 1 mg Ozempic injection
• 2 mg Ozempic injection
• 1.5 mg Wegovy tablets
• 4 mg Wegovy tablets
• 9 mg Wegovy tablets
• 25 mg Wegovy tablets
• 0.25 mg Wegovy injection
• 0.5 mg Wegovy injection
• 1 mg Wegovy injection
• 1.7 mg Wegovy injection
• 2.4 mg Wegovy injection

Novo Nordisk took legal action against Hims & Hers in February of this year,² claiming that the telehealth company was mass marketing unapproved versions of Novo’s GLP-1 offerings.

In a press issued at the time, John F. Kuckelman, senior vice president and group general counsel of global legal, IP, and security for Novo Nordisk, said, “Throughout Novo Nordisk’s 103-year-long history, patient safety has always been our top priority. Hims & Hers is mass marketing unapproved knock-off versions of Wegovy® and Ozempic® that evade the FDA’s gold standard review process––that’s dangerous and deceptive to patients, and undermines the scientific innovation and regulatory rigor in place to ensure these treatments are safe and effective. We’ve taken legal action to protect the American public and our intellectual property and will continue to work with regulators, law enforcement, and other key stakeholders to ensure patients have access to FDA approved safe and effective medicines.”

In early February,³ FDA issued a statement specifically citing Hims & Hers for selling non-approved, compounded GLP-1s. The agency announced plans to restrict GLP-1 ingredients intended to be used in these compounded medications.

In a statement, FDA wrote, “FDA is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025. In promotional materials, companies cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA. They also cannot state compounded drugs use the same active ingredient as the FDA-approved drugs or that compounded drugs are clinically proven to produce results for the patient.”

Several days following this announcement, Hims & Hers made an announcement of its own saying that it would no longer be providing access to these compounded medications. In a statement issued at the time, a spokesperson for Hims wrote, “Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalized care.”

Sources

1. Novo Nordisk expands US patient access to FDA-approved semaglutide medicines through Hims & Hers in response to a shift in their US GLP-1 business model. Novo Nordisk. March 9, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916512
2. Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy and Ozempic. Novo Nordisk. February 9, 2026. Accessed March 9, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916493
3. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs. FDA. February 6, 2026. Accessed March 9, 2026. https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs